Wire · opportunities
Troubling Findings in Study of GLP-1 Compounders
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 July 2026 · Fusion42 review
A secret shopper study found that 92% of weight-loss clinics and medical spas continue offering compounded semaglutide and 87% offer compounded tirzepatide despite FDA shortages ending, with over half adding unapproved ingredients like B vitamins and some operating from unlicensed or disciplined facilities with documented sterile compounding violations.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you build a GLP-1 telehealth or dispensing platform, your supply chain just became a regulatory liability: the FDA is moving from tolerance to enforcement by end of May 2025, and the compounders you're buying from are documenting sterile compounding violations. Your customers will need approved drugs or you're both exposed.
◆ Coverage
1 source · 21 Jul 2026
◆ Related on Wire
◆ Topics